journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/28314842/performance-of-mid-treatment-breast-ultrasound-and-axillary-ultrasound-in-predicting-response-to-neoadjuvant-chemotherapy-by-breast-cancer-subtype
#1
Rosalind P Candelaria, Roland L Bassett, William Fraser Symmans, Maheshwari Ramineni, Stacy L Moulder, Henry M Kuerer, Alastair M Thompson, Wei Tse Yang
BACKGROUND: The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB). METHODS: Patients with invasive breast cancer who underwent neoadjuvant chemotherapy and had pre-treatment and mid-treatment breast and axillary ultrasound were included in this single-institution, retrospective cohort study. Linear regression analysis assessed associations between RCB with (a) change in index breast tumor size, (b) change in index node size, and (c) absolute number of abnormal nodes at mid-treatment...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314841/academic-cancer-center-phase-i-program-development
#2
Arthur E Frankel, Keith T Flaherty, George J Weiner, Robert Chen, Nilofer S Azad, Michael J Pishvaian, John A Thompson, Matthew H Taylor, Daruka Mahadevan, A Craig Lockhart, Ulka N Vaishampayan, Jordan D Berlin, David C Smith, John Sarantopoulos, Matthew Riese, Mansoor N Saleh, Chul Ahn, Eugene P Frenkel
Multiple factors critical to the effectiveness of academic phase I cancer programs were assessed among 16 academic centers in the U.S. Successful cancer centers were defined as having broad phase I and I/II clinical trial portfolios, multiple investigator-initiated studies, and correlative science. The most significant elements were institutional philanthropic support, experienced clinical research managers, robust institutional basic research, institutional administrative efforts to reduce bureaucratic regulatory delays, phase I navigators to inform patients and physicians of new studies, and a large cancer center patient base...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314840/end-of-life-care-matters-palliative-cancer-care-results-in-better-care-and-lower-costs
#3
Shalini Dalal, Eduardo Bruera
No abstract text is available yet for this article.
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314839/on-the-interpretation-of-the-hazard-ratio-and-communication-of-survival-benefit
#4
Andreas Sashegyi, David Ferry
This brief communication will clarify the difference between a relative hazard and a relative risk. We highlight the importance of this difference, and demonstrate in practical terms that 1 minus the hazard ratio should not be interpreted as a risk reduction in the commonly understood sense of the term. This article aims to provide a better understanding of the type of risk reduction that a hazard ratio implies, thereby clarifying the intent in the communication among practitioners and researchers and establishing an accurate and realistic foundation for communicating with patients...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314838/a-phase-i-study-of-abiraterone-acetate-combined-with-bez235-a-dual-pi3k-mtor-inhibitor-in-metastatic-castration-resistant-prostate-cancer
#5
Xiao X Wei, Andrew C Hsieh, Won Kim, Terence Friedlander, Amy M Lin, Mirela Louttit, Charles J Ryan
LESSONS LEARNED: The combination of standard dose abiraterone acetate and BEZ235, a pan-class I PI3K and mTORC1/2 inhibitor, was poorly tolerated in men with progressive mCRPC.Although the clinical development of BEZ235 has been discontinued in prostate cancer, agents that more selectively target PI3K-AKT-mTOR signaling may have a more favorable therapeutic index and should continue to be explored. BACKGROUND: Androgen receptor (AR) and phosphatidylinositol-3 kinase (PI3K) signaling are two commonly perturbed pathways in prostate cancer...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314837/risk-reducing-strategies-for-ovarian-cancer-in-brca-mutation-carriers-a-balancing-act
#6
Roi Tschernichovsky, Annekathryn Goodman
OBJECTIVE: The objective of this study was to review the role of bilateral salpingo-oophorectomy in BRCA mutation (mBRCA) carriers and alternative interventions in risk reduction of ovarian cancer (OC). MATERIALS AND METHODS: A systematic review using PubMed, MEDLINE, EMBASE, and the Cochrane library was conducted to identify studies of different strategies to prevent OC in mBRCA carriers, including bilateral salpingo-oophorectomy, prophylactic salpingectomy with delayed oophorectomy, intensive surveillance, and chemoprevention...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314836/safe-heart-rationale-and-design-of-a-pilot-study-investigating-cardiac-safety-of-her2-targeted-therapy-in-patients-with-her2-positive-breast-cancer-and-reduced-left-ventricular-function
#7
Filipa Lynce, Ana Barac, Ming T Tan, Federico M Asch, Karen L Smith, Chau Dang, Claudine Isaacs, Sandra M Swain
BACKGROUND: Human epidermal growth receptor 2 (HER2) targeted therapies have survival benefit in adjuvant and metastatic HER2 positive breast cancer but are associated with cardiac dysfunction. Current U.S. Food and Drug Administration recommendations limit the use of HER2 targeted agents to patients with normal left ventricular (LV) systolic function. METHODS: The objective of the SAFE-HEaRt study is to evaluate the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and mildly reduced left ventricular ejection fraction (LVEF) with optimized cardiac therapy...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28314835/endocrine-therapy-in-the-current-management-of-postmenopausal-estrogen-receptor-positive-metastatic-breast-cancer
#8
Virginia G Kaklamani, William J Gradishar
Metastatic breast cancer (MBC) results in substantial morbidity and mortality for women afflicted with this disease. A majority of MBCs are hormone-responsive and estrogen receptor-positive, making endocrine therapy (ET) an integral component of systemic therapy. With a primary goal of minimizing the effects of estrogen on hormone-responsive MBC, ETs are among the first targeted treatments that aim to inhibit the influence of estrogen receptor activation on tumor proliferation. Several biochemical mechanisms have been the focus of drug development for treatment, including selective estrogen-receptor modulation, aromatase inhibition, and selective estrogen-receptor degradation...
March 17, 2017: Oncologist
https://www.readbyqxmd.com/read/28283585/the-incidence-and-health-care-resource-burden-of-the-myelodysplastic-syndromes-in-patients-in-whom-first-line-hypomethylating-agents-fail
#9
Christopher R Cogle, Sandra E Kurtin, Tanya G K Bentley, Michael S Broder, Eunice Chang, Scott Megaffin, Steven Fruchtman, Michael E Petrone, Sudipto Mukherjee
BACKGROUND: Although hypomethylating agents (HMAs) are effective and approved therapies for patients with myelodysplastic syndromes (MDS), many patients do not benefit from treatment, and nearly all ultimately stop responding to HMAs. The incidence and cost burden of HMA failure are unknown yet needed to appreciate the magnitude and significance of such failure. METHODS: We analyzed a de-identified dataset of over 5 million individuals with private health insurance in the U...
March 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28283584/clinical-benefit-in-response-to-palbociclib-treatment-in-refractory-uterine-leiomyosarcomas-with-a-common-cdkn2a-alteration
#10
Julia A Elvin, Laurie M Gay, Rita Ort, Joseph Shuluk, Jennifer Long, Lauren Shelley, Ronald Lee, Zachary R Chalmers, Garrett M Frampton, Siraj M Ali, Alexa B Schrock, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Richard Frank
BACKGROUND: Uterine leiomyosarcoma (uLMS) responds poorly to conventional chemotherapeutic agents, and personalized therapies have yet to be systematically explored. Comprehensive genomic profiling (CGP) can identify therapeutic targets and provide insight into the biology of this highly aggressive tumor. We report a case of uLMS treated with the CGP-matched therapy palbociclib, a CDK4/6 inhibitor, with sustained clinical benefit in this rare and deadly malignancy. MATERIALS AND METHODS: This study analyzed 279 clinically advanced/recurrent uLMS samples...
March 10, 2017: Oncologist
https://www.readbyqxmd.com/read/28275120/role-of-mgmt-methylation-status-at-time-of-diagnosis-and-recurrence-for-patients-with-glioblastoma-clinical-implications
#11
Alba A Brandes, Enrico Franceschi, Alexandro Paccapelo, Giovanni Tallini, Dario De Biase, Claudio Ghimenton, Daniela Danieli, Elena Zunarelli, Giovanni Lanza, Enrico Maria Silini, Carmelo Sturiale, Lorenzo Volpin, Franco Servadei, Andrea Talacchi, Antonio Fioravanti, Maria Pia Foschini, Stefania Bartolini, Annalisa Pession, Mario Ermani
BACKGROUND: MGMT methylation status represents a powerful prognostic factor in newly diagnosed glioblastoma (GBM). Recently, its role in recurrent tumors has also been suggested; however, few data investigating the stability of this biomarker during the clinical course of the disease are available. In this study, we evaluated the rate of change of MGMT methylation status between diagnosis and first recurrence in patients who received tumor resection for recurrent GBM. METHODS: We included patients who received temozolomide concurrent with and adjuvant to radiotherapy after diagnosis of GBM and had a second surgery performed at least 3 months after radiotherapy completion...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28275119/phase-i-dose-escalation-study-of-pilaralisib-sar245408-xl147-in-combination-with-paclitaxel-and-carboplatin-in-patients-with-solid-tumors
#12
Jennifer Wheler, David Mutch, Joanne Lager, Christelle Castell, Li Liu, Jason Jiang, Anne M Traynor
LESSONS LEARNED: Despite involvement of PI3K pathway activation in tumorigenesis of solid tumors, single-agent PI3K inhibitors have shown modest clinical activity.Preclinical evidence suggests that combining PI3K pathway inhibitors and chemotherapy can enhance antitumor effects.In patients with solid tumors, the PI3K inhibitor pilaralisib had a favorable safety profile but did not enhance the antitumor activity of paclitaxel plus carboplatin.Further clinical evaluation is warranted to identify effective combination strategies with PI3K pathway inhibitors...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28275118/modern-management-of-anthracycline-induced-cardiotoxicity-in-lymphoma-patients-low-occurrence-of-cardiotoxicity-with-comprehensive-assessment-and-tailored-substitution-by-nonpegylated-liposomal-doxorubicin
#13
Jacopo Olivieri, Gian Piero Perna, Caterina Bocci, Claudia Montevecchi, Attilio Olivieri, Pietro Leoni, Guido Gini
BACKGROUND: Anthracyclines (AC) are still undeniable drugs in lymphoma treatment, despite occasionally causing cardiotoxicity. Liposomal AC may reduce cardiotoxicity while retaining clinical efficacy; also, biomarker monitoring during chemotherapy allows early detection of cardiac damage, enabling strategies to prevent left ventricular ejection fraction (LVEF) deterioration. MATERIALS AND METHODS: We conducted a prospective observational trial in a real-life population of lymphoma patients, combining advanced echocardiography and biomarkers (Troponin I [TnI]) for early detection of cardiotoxicity; we applied a prespecified policy to minimize cardiotoxicity, selecting patients with higher baseline risk to replace doxorubicin with nonpegylated liposomal doxorubicin (NPLD) and starting cardioprotective treatment when subclinical cardiotoxicity was detected...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28275117/randomized-phase-ii-trial-of-parsatuzumab-anti-egfl7-or-placebo-in-combination-with-folfox-and-bevacizumab-for-first-line-metastatic-colorectal-cancer
#14
Rocío García-Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Niall Tebbutt, Fadi Braiteh, Guillem Argiles, Zev A Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert Hurwitz
LESSONS LEARNED: These negative phase II results for parsatuzumab highlight the challenges of developing an agent intended to enhance the efficacy of vascular endothelial growth factor inhibition without the benefit of validated pharmacodynamic biomarkers or strong predictive biomarker hypotheses.Any further clinical development of anti-EGFL7 is likely to require new mechanistic insights and biomarker development for antiangiogenic agents. BACKGROUND: EGFL7 (epidermal growth factor-like domain 7) is a tumor-enriched vascular extracellular matrix protein that supports endothelial cell survival...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28275116/retrospective-review-of-atypical-femoral-fracture-in-metastatic-bone-disease-patients-receiving-denosumab-therapy
#15
Samantha Peiling Yang, Tae Won B Kim, Patrick J Boland, Azeez Farooki
BACKGROUND: Denosumab therapy is used to reduce skeletal-related events in metastatic bone disease (MBD). There have been reports of atypical femoral fracture (AFF) in osteoporotic patients treated with denosumab but none in the context of higher dose and more frequent denosumab therapy for MBD. The goal of this study was to assess the incidence of AFF in MBD. PATIENTS AND METHODS: We conducted a retrospective review of 253 patients who received a minimum of 12 doses of denosumab at 120 mg each for MBD...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28275115/safety-and-tolerability-of-pd-1-pd-l1-inhibitors-compared-with-chemotherapy-in-patients-with-advanced-cancer-a-meta-analysis
#16
Tomohiro F Nishijima, Shlomit S Shachar, Kirsten A Nyrop, Hyman B Muss
BACKGROUND: Compared with chemotherapy, significant improvement in survival outcomes with the programmed death receptor-1 (PD-1) inhibitors nivolumab and pembrolizumab and the programmed death-ligand 1 (PD-L1) inhibitor atezolizumab has been shown in several types of advanced solid tumors. We conducted a systematic review and meta-analysis to compare safety and tolerability between PD-1/PD-L1 inhibitors and chemotherapy. METHODS: PubMed and American Society of Clinical Oncology (ASCO) databases were searched 1966 to September 2016...
March 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28246207/a-phase-ii-randomized-double-blind-placebo-controlled-study-of-simtuzumab-in-combination-with-folfiri-for-the-second-line-treatment-of-metastatic-kras-mutant-colorectal-adenocarcinoma
#17
J Randolph Hecht, Al B Benson, Dmitry Vyushkov, Yingsi Yang, Johanna Bendell, Udit Verma
LESSONS LEARNED: The safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group.The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients with metastatic KRAS mutant colorectal carcinoma. BACKGROUND: Simtuzumab, a humanized IgG4 monoclonal antibody to lysyl oxidase-like 2 (LOXL2), blocks desmoplastic reaction in colorectal carcinoma (CRC) cells in vitro...
February 28, 2017: Oncologist
https://www.readbyqxmd.com/read/28246206/a-phase-ii-randomized-double-blind-placebo-controlled-study-of-simtuzumab-or-placebo-in-combination-with-gemcitabine-for-the-first-line-treatment-of-pancreatic-adenocarcinoma
#18
Al B Benson, Zev A Wainberg, J Randolph Hecht, Dmitry Vyushkov, Hua Dong, Johanna Bendell, Fred Kudrik
LESSONS LEARNED: The safety profile in the gemcitabine/simtuzumab group was similar to that in the gemcitabine/placebo group.The addition of simtuzumab to gemcitabine does not improve clinical outcomes in patients with metastatic pancreatic adenocarcinoma BACKGROUND: The humanized IgG4 monoclonal antibody simtuzumab inhibits the extracellular matrix-remodeling enzyme lysyl oxidase-like 2 maintaining pathological stroma in tumors. METHODS: Adult patients with metastatic pancreatic adenocarcinoma (mPaCa) were randomly assigned to receive intravenous gemcitabine, 1,000 mg/m(2), in combination with 200 or 700 mg simtuzumab or placebo...
February 28, 2017: Oncologist
https://www.readbyqxmd.com/read/28242792/survival-gains-from-first-line-systemic-therapy-in-metastatic-non-small-cell-lung-cancer-in-the-u-s-1990-2015-progress-and-opportunities
#19
Joshua A Roth, Bernardo H L Goulart, Arliene Ravelo, Holli Kolkey, Scott D Ramsey
BACKGROUND: Approximately 190,000 Americans are diagnosed with non-small cell lung cancer (NSCLC) annually, and about half have metastatic (Stage IV) disease. These patients have historically had poor survival prognosis, but several new therapies introduced since 2000 provide options for improved outcomes. The objectives of this study were to quantify survival gains from 1990, when best supportive care (BSC) only was standard, to 2015 and to estimate the impact of expanded use of systemic therapies in clinically appropriate patients...
February 27, 2017: Oncologist
https://www.readbyqxmd.com/read/28242791/response-to-tyrosine-kinase-inhibitors-in-myeloproliferative-neoplasia-with-8p11-translocation-and-cep110-fgfr1-rearrangement
#20
Marc Wehrli, Elisabeth Oppliger Leibundgut, Heinrich H Gattiker, Markus G Manz, Antonia M S Müller, Jeroen S Goede
This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation...
February 27, 2017: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"